Endpoints News· @endpts · X·· 12 天前AI 评分52
AI 导读
Caldera和Evommune分别与中国生物技术公司签署授权协议,各自支付3000万美元首付款,引进自身免疫领域药物。Endpoints News报道了这两笔交易,原文链接为https://endpoints.news/caldera-evommune-sign-china-licensing-deals-for-autoimmune-drugs/。
正文
Caldera and Evommune each paid $30M upfront to license autoimmune drugs from Chinese biotechs. https://endpoints.news/caldera-evommune-sign-china-licensing-deals-for-autoimmune-drugs/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com